<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24623838</article-id><article-id pub-id-type="pmc">PMC4001185</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2013537704</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000000312</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>12</subject><subject>32</subject><subject>59</subject><subject>120</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Wardlaw</surname><given-names>Joanna M.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Stroke, Editorial Board, ended August 2013</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Allerhand</surname><given-names>Michael</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Doubal</surname><given-names>Fergus N.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>1 MRC research grant</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Valdes Hernandez</surname><given-names>Maria</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>I am a member of the World Journal of Radiology Editorial Board (ID:02666832) from 01.01.2014 until 31.12.2017</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Row Fogo Charitable Trust</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Morris</surname><given-names>Zoe</given-names></name><degrees>FRCR</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Gow</surname><given-names>Alan J.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Bastin</surname><given-names>Mark</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Starr</surname><given-names>John M.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Archives of Gerontology and Geriatrics, Editor-in-Chief, 2011-present.</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Dennis</surname><given-names>Martin S.</given-names></name><degrees>MD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Stroke 2008-2009 - Editorial Board; (2) Cerebrovascular diseases 2009 - Editorial Board</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>Stroke - a practical guide. Warlow et al, Blackwells, 2008</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>Covidien, provided materials for an RCT of which I am a PI from 2001-present</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) MRC (UK)Ref No: G0200531 2003-9; (2) CSO (Scotland)CZG\2\378 2008-9; (3) NIHR (UK) 08/14/03 2010-2014</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>(1) CHSS Res07/A108 2007-9; (2) TSA (UK) 20111 2012-2014</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Deary</surname><given-names>Ian J.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>Deary, I. J., Bastin, M., Starr, J. M., Wardlaw, J. M., &#x00026; Penke, L. Brain white matter imaging and cognitive ageing in the Lothian Birth Cohort 1936: II. Medical Research Council. &#x000ef;&#x000bf;&#x000bd;808,224. April 2011-March 2014. (G1001245.) Deary, I. J. Grant to establish Medical Research Council Centre for Cognitive Ageing and Cognitive Epidemiology (Director I. J. Deary). Medical Research Council. &#x000ef;&#x000bf;&#x000bd;3,400,000 approx. August 2008-July 2013 (G0700704/84698.)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>Deary, I. J., &#x00026; Starr, J. M., &#x00026; Wardlaw, J. M. The Disconnected Mind, Phase 2. Age UK. &#x000ef;&#x000bf;&#x000bd;2,500,000. April 2011-March 2016.</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &#x00026; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Centre for Clinical Brain Sciences (J.M.W., F.N.D., M.V.H., Z.M., M.B., M.S.D.) and Centre for Cognitive Ageing and Cognitive Epidemiology (M.A., M.V.H., A.J.G., M.B., J.M.S., I.J.D.), University of Edinburgh, UK.</aff></contrib-group><author-notes><corresp>Correspondence to Dr. Wardlaw: <email>joanna.wardlaw@ed.ac.uk</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>4</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>15</day><month>4</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="ppub"/>. --><volume>82</volume><issue>15</issue><fpage>1331</fpage><lpage>1338</lpage><history><date date-type="received"><day>11</day><month>7</month><year>2013</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2014 American Academy of Neurology</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="20140415.0-00010.pdf"/><abstract><sec><title>Objective:</title><p>To determine the magnitude of potentially causal relationships among vascular risk factors (VRFs), large-artery atheromatous disease (LAD), and cerebral white matter hyperintensities (WMH) in 2 prospective cohorts.</p></sec><sec><title>Methods:</title><p>We assessed VRFs (history and measured variables), LAD (in carotid, coronary, and leg arteries), and WMH (on structural MRI, visual scores and volume) in: (a) community-dwelling older subjects of the Lothian Birth Cohort 1936, and (b) patients with recent nondisabling stroke. We analyzed correlations, developed structural equation models, and performed mediation analysis to test interrelationships among VRFs, LAD, and WMH.</p></sec><sec><title>Results:</title><p>In subjects of the Lothian Birth Cohort 1936 (n = 881, mean age 72.5 years [SD &#x000b1;0.7 years], 49% with hypertension, 33% with moderate/severe WMH), VRFs explained 70% of the LAD variance but only 1.4% to 2% of WMH variance, of which hypertension explained the most. In stroke patients (n = 257, mean age 74 years [SD &#x000b1;11.6 years], 61% hypertensive, 43% moderate/severe WMH), VRFs explained only 0.1% of WMH variance. There was no direct association between LAD and WMH in either sample. The results were the same for all WMH measures used.</p></sec><sec><title>Conclusions:</title><p>The small effect of VRFs and LAD on WMH suggests that WMH have a large &#x0201c;nonvascular,&#x0201d; nonatheromatous etiology. VRF modification, although important, may be limited in preventing WMH and their stroke and dementia consequences. Investigation of, and interventions against, other suspected small-vessel disease mechanisms should be addressed.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>White matter hyperintensities (WMH) are a major component of cerebral small-vessel disease (SVD) and substantially increase the risk of dementia, stroke,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> and physical disability.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> Despite this considerable clinical and societal impact, the causes of SVD and WMH are poorly understood.<sup><xref rid="R3" ref-type="bibr">3</xref></sup></p><p>WMH are associated with several common vascular risk factors (VRFs) offering potentially modifiable targets: hypertension,<sup><xref rid="R4" ref-type="bibr">4</xref><xref ref-type="bibr" rid="R5">&#x02013;</xref><xref rid="R9" ref-type="bibr">9</xref></sup> diabetes, hypercholesterolemia, smoking, and possibly carotid stenosis.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Hypertension was associated with WMH progression<sup><xref rid="R6" ref-type="bibr">6</xref><xref ref-type="bibr" rid="R7">&#x02013;</xref><xref rid="R9" ref-type="bibr">9</xref></sup>; better blood pressure (BP) control delayed WMH progression in observational studies<sup><xref rid="R9" ref-type="bibr">9</xref></sup> and in one randomized controlled trial (RCT).<sup><xref rid="R11" ref-type="bibr">11</xref></sup> However, there are anomalies: in larger RCTs, antihypertensive treatment did not prevent WMH progression,<sup><xref rid="R12" ref-type="bibr">12</xref></sup> intensive BP reduction did not prevent recurrent lacunar stroke,<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and the associations between BP and WMH were often weak<sup><xref rid="R14" ref-type="bibr">14</xref></sup> or disappeared with correction for age and baseline WMH, both strong predictors of WMH progression.<sup><xref rid="R15" ref-type="bibr">15</xref><xref ref-type="bibr" rid="R16">&#x02013;</xref><xref rid="R17" ref-type="bibr">17</xref></sup> Statins did not prevent WMH progression,<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and dual (vs mono) antiplatelet therapy increased death in patients with lacunar stroke without preventing recurrence.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup></p><p>These discrepancies question the strength of associations among VRFs, atheroma, and SVD, contrasting with the effectiveness of antihypertensive, antiplatelet drugs and statins in preventing atheromatous ischemic stroke. We hypothesized that if WMH mainly occur secondary to VRFs or are a &#x0201c;small-vessel&#x0201d; form of atheroma, then either of these or both should explain most WMH variance. We determined how much WMH variability was attributable to VRFs and/or large-artery atheromatous disease (LAD) in 2 cohorts.</p><sec sec-type="methods" id="s1"><title>METHODS</title><p>The derivation cohort is the Lothian Birth Cohort 1936 (LBC1936),<sup><xref rid="R21" ref-type="bibr">21</xref></sup> community-dwelling older subjects born in 1936, now being studied to determine lifetime influences on aging. The replication cohort is a prospective study of patients with recent nondisabling ischemic stroke, the Mild Stroke Study (MSS).<sup><xref rid="R22" ref-type="bibr">22</xref></sup></p><p>The LBC1936 subjects were aged 71 to 74 years (mean 72.5, SD 0.72) at assessment. The MSS patients were aged 34 to 95 years (mean 74, SD 11.62). In both groups, we obtained medical history, physiologic measurements, blood samples, brain MRI, and carotid Doppler ultrasound imaging (full details in references <xref rid="R21" ref-type="bibr">21</xref><xref ref-type="bibr" rid="R22">&#x02013;</xref><xref rid="R23" ref-type="bibr">23</xref>).</p><p>We recorded hypertension, diabetes, hypercholesterolemia (all medically diagnosed and/or on relevant drugs), ischemic heart disease, peripheral vascular disease or other circulatory problems (all diagnosed by general practitioner or hospital doctor), and smoking (current vs stopped &#x0003e;1 year ago or never smoked). History of stroke was also collected in the LBC1936 cohort. All MSS participants had an index stroke (on clinical criteria and MRI with diffusion imaging<sup><xref rid="R22" ref-type="bibr">22</xref></sup>) as a study entry criterion.</p><p>In the LBC1936 cohort, we measured systolic and diastolic BP, each 3 times sitting and standing during a 4-hour Clinical Research Facility assessment. We also measured the following: ankle-brachial pressure index (ABPI), carotid intima-media thickness (IMT) in the common carotid artery and carotid bulb on both sides (mean of 3 measures by Framingham<sup><xref rid="R24" ref-type="bibr">24</xref></sup> and by manual caliper measurements), carotid flow velocities, maximum stenosis affecting the internal carotid artery/bulb/common carotid artery,<sup><xref rid="R25" ref-type="bibr">25</xref></sup> hemoglobin A1c (HbA1c), plasma total cholesterol and albumin, urinary albumin, microalbuminuria, and estimated glomerular filtration rate (eGFR). All measures were performed blinded to all other data. In the MSS subjects, we also performed echocardiography where clinically indicated and measured all of the above (including carotid Doppler ultrasound on the same scanner with the same operators) except ABPI, HbA1c, IMT, eGFR, microalbuminuria, and albumin, and only one BP reading was available, but we had more detailed history and medical examination.</p><p>All LBC1936 and MSS subjects underwent brain MRI on the same 1.5-tesla GE Signa Horizon HDx clinical scanner (General Electric, Milwaukee, WI) and had T1-, T2-, and T2*-weighted and fluid-attenuated inversion recovery axial whole-brain imaging.<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> A neuroradiologist, trained in WMH rating, quantified the WMH on fluid-attenuated inversion recovery using the Fazekas score.<sup><xref rid="R26" ref-type="bibr">26</xref></sup> A second neuroradiologist cross-checked a random 20% of ratings, uncertain ratings, and cases with suspected infarct. In the LBC1936, we also measured WMH volumes in cubic millimeters using a validated multispectral image processing method (<ext-link ext-link-type="uri" xlink:href="http://sourceforge.net/projects/bric1936/">http://sourceforge.net/projects/bric1936/</ext-link>) that maps combinations of magnetic resonance sequences to the red-green color space for tissue segmentation.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R27" ref-type="bibr">27</xref></sup> We checked all segmented images visually for accuracy blinded to all clinical details, manually removed any errors, and masked all imaging-detected infarcts to avoid confounding the WMH volumes.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><sec id="s1-1"><title>Standard protocol approvals, registrations, and patient consents.</title><p>Both studies were approved by Lothian Research Ethics (LBC1936 REC 07/MRE00/58; MSS 2002/8/64) and LBC1936 additionally by the Scottish Multicentre (MREC/01/0/56) Research Ethics. Written informed consent was obtained from all participants.</p></sec><sec id="s1-2"><title>Analytical approach.</title><p>We used all available data, because the pattern of missing values was acceptably random (e.g., more LBC1936 subjects completed carotid than brain imaging). WMH were not associated with carotid disease on right or left sides separately so we combined sides. We used the average of sitting BPs after exploring multiple individual measures of systolic and diastolic and mean BPs at sitting and standing positions. We examined correlation matrices and excluded variables with no/low correlation from further analysis, e.g., eGFR and microalbuminuria. Where both variables were continuous, we used the Pearson correlation coefficient; dichotomous, we used tetrachoric correlation; and 1 dichotomous/1 continuous, we used biserial correlation. The <italic>p</italic> values for the latter 2 correlations were determined from their variance and standard error.<sup><xref rid="R29" ref-type="bibr">29</xref></sup></p><p>We used structural equation models to test the contribution of VRFs and LAD to the WMH burden. Such models are described using path diagrams, e.g., <xref ref-type="fig" rid="F1 F2">figures 1 and 2</xref>, where the square boxes represent measured observations, e.g., BP. Each circle represents a &#x0201c;latent construct,&#x0201d; e.g., LAD or VRFs, that underlies a combination of correlated individual measured variables. Single-headed arrows represent simple regression relationships, and double-headed arrows represent correlations. In structural equation models, it is conventional to divide the modeling into 2 parts. <italic>Measurement models</italic> are used to check whether the variance shared by several measured variables constitutes an underlying latent trait. <italic>Structural models</italic> are used to test hypothesized relationships among latent and measured variables. <xref ref-type="fig" rid="F1">Figure 1</xref> shows measurement models for LAD and VRFs, where each circle represents an underlying latent construct that is a weighted combination of the correlated measured variables. <xref ref-type="fig" rid="F2">Figure 2</xref> shows structural models of relationships between these latent constructs of LAD, VRFs, and WMH. The models shown in <xref ref-type="fig" rid="F2">figure 2, A and B</xref>, test the hypothesis that the association between LAD and WMH may be explained by common association with VRFs. Under this hypothesis, we expected the total association between LAD and WMH (<xref ref-type="fig" rid="F2">figure 2A</xref>) to be reduced when VRFs were controlled in both variables (<xref ref-type="fig" rid="F2">figure 2B</xref>). The models shown in <xref ref-type="fig" rid="F2">figure 2, C and D</xref>, test the hypothesis that any direct relationship between VRFs and WMH (<xref ref-type="fig" rid="F2">figure 2C</xref>) is mediated by LAD (<xref ref-type="fig" rid="F2">figure 2D</xref>; details in appendix e-1 on the <italic>Neurology</italic>&#x000ae; Web site at <ext-link ext-link-type="uri" xlink:href="http://www.neurology.org/">Neurology.org</ext-link>).</p><fig id="F1" position="float"><label>Figure 1</label><caption><title>LBC1936 cohort: Diagram of measurement models for the VRF and LAD constructs</title><p>Standardized loadings and residual correlations are shown. Numbers adjacent to paths may be squared to obtain the shared variance between adjacent variables. Double-headed arrows are correlations; single-headed arrows are hypothesized causal pathways. The convention used represents manifest (measured) variables as rectangles and constructed variables (VRFs or LAD) as circles. Model fit parameters are shown adjacent to the constructed variable: a nonsignificant &#x003c7;<sup>2</sup> is a sign of a well-fitting model; the Max MI (which indicates the degree of greatest local strain within the model in terms of a potential reduction in model &#x003c7;<sup>2</sup>); the CFI (&#x02265;0.90 indicates acceptable fit); and the RMSEA (&#x0003c;0.06 indicates acceptable fit). CFI = comparative fit index; HbA1c = hemoglobin A1c; LAD = large-artery atheromatous disease; LBC1936 = Lothian Birth Cohort 1936; Max MI = maximum modification index; RMSEA = root mean square error of approximation; VRF = vascular risk factor.</p></caption><graphic xlink:href="NEUROLOGY2013537704FF1"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>Structural models in the LBC1936</title><p>(A) This model is the total association between LAD and WMH. (B) Hierarchical association with VRFs controlled. (C) Total effect of VRFs on WMH. (D) The mediation model (see the text). Standardized regression coefficients (parameter weights) are shown adjacent to each path. Each arrow is directed from a predictor variable to the outcome variable. In model B, the 0.828 indicates that approximately 70% of the variance in LAD is explained by VRFs and the 0.111 indicates that approximately 2% of the variance in WMH is explained by VRFs. The 0.292 and 0.984 adjacent to the lateral arrows in model B indicate the variance that is unexplained by VRFs on LAD and WMH, respectively. The estimates shown in the figure are for WMH measured using combined periventricular and deep Fazekas scores. The estimates for the model using other WMH measures are shown in <xref ref-type="table" rid="T2">table 2</xref>. <italic>R</italic><sup>2</sup> is the WMH model <italic>R</italic><sup>2</sup> value; s<sup>2</sup> is the residual variance. LAD = large-artery atheromatous disease; LBC1936 = Lothian Birth Cohort 1936; VRF = vascular risk factor; WMH = white matter hyperintensity.</p></caption><graphic xlink:href="NEUROLOGY2013537704FF2"/></fig><p>In the LBC1936, we grouped the measured variables into those that represented (1) VRFs, (2) LAD in the arteries supplying the brain, heart, or legs, and (3) WMH measures. VRFs included history variables (hypertension, diabetes, hypercholesterolemia, smoking) and measured variables (BP, HBA1c, and plasma cholesterol). LAD included history variables (ischemic heart disease, peripheral vascular disease, other circulatory problems) and measured variables (ABPI, carotid stenosis, and IMT; <xref ref-type="fig" rid="F1">figure 1</xref>).<sup><xref rid="R24" ref-type="bibr">24</xref></sup> The variables were grouped based on medical knowledge, correlations, a scree plot of the principal components, and the exploratory factor analysis.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> For WMH, because deep and periventricular WMH were highly correlated (<italic>r</italic> = 0.53, <italic>p</italic> &#x0003c; 0.001), we combined them into a summed Fazekas score. We also tested WMH volume as a percent of intracranial volume and of brain parenchymal volume. The correlation between the 2 percentage WMH scores was 0.998, and between the Fazekas scores and each of the 2 percentage scores was 0.760 and 0.765. The Fazekas score was ordinal, and both percentage measures were continuous variables. Both were positively skewed and zero-inflated (less than 18% of the sample were zeros), and these measures were treated as censored from below at zero using Tobit regression.</p><p>We performed a similar analysis in the MSS cohort by testing groupings of VRF and LAD measured variables and WMH (figure e-1).</p><p>We used Mplus version 6.1<sup><xref rid="R31" ref-type="bibr">31</xref></sup> to fit the measurement and structural models of regression relationships between the variables simultaneously. We estimated model parameters by weighted least-squares and assessed the indirect effect in the mediation model (model D) using a bias-corrected bootstrapped confidence interval derived by Monte Carlo sampling.<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup> We controlled for sex in all variables but not age (adjusting for age had negligible effect and all subjects were of very similar ages, SD = 0.71 years). We examined estimates of factor loadings (unstandardized, standardized, and squared multiple correlation coefficient) and several indices of model fit: the comparative fit index (&#x02265;0.90 indicates acceptable fit), the root mean square error of approximation (&#x0003c;0.06 indicates acceptable fit), and the maximum modification index (indicates the degree of greatest local strain within the model in terms of a potential reduction in model &#x003c7;<sup>2</sup>).</p></sec></sec><sec sec-type="results" id="s2"><title>RESULTS</title><sec id="s2-1"><title>Primary analysis.</title><p>In the LBC1936, 861 subjects (415, 48% male) of mean age 72.5 years (SD 0.7, range 71&#x02013;74 years) had full clinical assessment and carotid imaging; 681 subjects completed brain imaging and provided WMH scores and volumes. Of the 861, 422 (49%) had hypertension, 94 (11%) had diabetes, 248 (29%) had ischemic heart disease, the median carotid stenosis was 20%, and 33% had moderate or severe WMH scores (<xref ref-type="table" rid="T1">table 1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>LBC1936 and MSS subjects' demographics and prevalence of features indicating large-artery disease, vascular risk factors, and white matter hyperintensities</p></caption><graphic xlink:href="NEUROLOGY2013537704TT1A"/><graphic xlink:href="NEUROLOGY2013537704TT1B"/></table-wrap><p>Multivariate measurement models to derive the VRF and LAD latent variables (<xref ref-type="fig" rid="F1">figure 1</xref>) indicate that all observed variables contributed significantly to the latent variable (<italic>p</italic> &#x0003c; 0.05) except for smoking (<italic>p</italic> = 0.66), which nonetheless we included in the VRF model. The models all fitted the data well (<xref ref-type="fig" rid="F1">figure 1</xref>).</p><p>Structural models (<xref ref-type="fig" rid="F2">figure 2</xref>) show the standardized estimates for WMH measured using Fazekas scores. Without accounting for VRFs (<xref ref-type="fig" rid="F2">figure 2A</xref>), there was a small but reliable shared variance of approximately 4% and 6% between LAD and WMH, depending on which WMH measure was used (all 3 WMH measures were statistically significant; <xref ref-type="table" rid="T2">table 2</xref>).</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Results for hierarchical (structural) models A and B in <sup>figure 2</sup></p></caption><graphic xlink:href="NEUROLOGY2013537704TT2"/></table-wrap><p>However, when VRFs were accounted for (<xref ref-type="fig" rid="F2">figure 2B</xref>), the total association between LAD and WMH became smaller and nonsignificant with all 3 WMH measures (<xref ref-type="table" rid="T2">table 2</xref>). Therefore, the small association between LAD and WMH seen in model A before VRFs were considered was mainly explained by VRFs acting through LAD. In addition, VRFs were a far stronger predictor of LAD than of WMH, accounting for approximately 70% of variation in LAD burden (standardized parameter weight 0.828) but less than 2% of variation in WMH (standardized parameter weight 0.111).</p><p>The mediation model (<xref ref-type="fig" rid="F2">figure 2, C and D</xref>) indicates that the standardized total effect of VRFs (<xref ref-type="fig" rid="F2">figure 2C</xref>, effect c in table e-1), explained no more than a small (2%) but significant variance in WMH. Exploring the effect of LAD as a mediating variable for VRFs (<xref ref-type="fig" rid="F2">figure 2D</xref>, appendix e-1, and <xref ref-type="table" rid="T1">table 1</xref>) did not explain the missing variance in WMH, instead emphasizing the presence of large influences on WMH that are not captured in history or concurrent measures of VRFs or LAD.</p><p>The magnitude of individual VRF contributions to WMH (table e-2, a and b) were all small; e.g., the largest individual contributions to WMH variance were hypertension (2.4%) and smoking (0.89%).</p></sec><sec id="s2-2"><title>Replication in the stroke cohort.</title><p>The MSS patients (n = 257) had similar mean age although a wider range (74.2, SD &#x000b1;11.6 years, range 34&#x02013;95 years) than the LBC1936, but more MSS patients were hypertensive (61%), smoked (57.4%), and had moderate to severe WMH scores (44.3% periventricular, 29.6% deep; <xref ref-type="table" rid="T1">table 1</xref>, figure e-1). A combined hierarchical factor analysis model showed that VRFs explained 35% of LAD variance (standardized parameter weight 0.594) but only 0.1% of WMH variance (standardized parameter weight &#x02212;0.033), with hypertension again being the strongest individual factor.</p></sec></sec><sec sec-type="discussion" id="s3"><title>DISCUSSION</title><p>WMH are a huge health problem, doubling the risk of dementia and trebling the risk of stroke. We were surprised to find that although VRFs explained 70% of the burden of LAD and hypertension was the strongest single risk factor for WMH, all common VRFs <italic>combined</italic> failed to account for 98% of WMH. Furthermore, there was no direct association between LAD and WMH; any apparent association was through a coassociation with VRFs. We found the same results in 2 separate cohorts, one community-dwelling, the other with stroke, regardless of how WMH were assessed. The mediation model highlighted the absence of key factors to account for most of the WMH variance.</p><p>The proportion of subjects with hypertension in the LBC1936 (49%) was similar to the proportion in other similar aging studies,<sup><xref rid="R34" ref-type="bibr">34</xref></sup> and the proportion MSS patients (61%) was similar to stroke patients elsewhere (55%&#x02013;66%).<sup><xref rid="R34" ref-type="bibr">34</xref></sup> Hypertension was the strongest risk factor for WMH in LBC1936, as in other observational studies.<sup><xref rid="R6" ref-type="bibr">6</xref><xref ref-type="bibr" rid="R7">&#x02013;</xref><xref rid="R9" ref-type="bibr">9</xref></sup> Consistent with our results, large increments in diastolic BP (e.g., 10 mm Hg above the mean baseline diastolic BP of 83 &#x000b1; 11 mm Hg) were associated with small differences in WMH in cross-sectional studies (e.g., 1.21% larger WMH volume)<sup><xref rid="R4" ref-type="bibr">4</xref></sup>; large increments in systolic BP (20 mm Hg) were associated with small increases in WMH volume (2.5 mL) at follow-up.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> The association between WMH and hypertension applied only to diastolic<sup><xref rid="R5" ref-type="bibr">5</xref></sup> or systolic BP,<sup><xref rid="R8" ref-type="bibr">8</xref></sup> indicating variation in strength of association.<sup><xref rid="R35" ref-type="bibr">35</xref></sup> Most studies adjusted for age, but not for baseline WMH, a strong predictor of WMH progression,<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup> although baseline adjustment should be handled cautiously because it may distort estimates of change in longitudinal studies.<sup><xref rid="R37" ref-type="bibr">37</xref></sup> Others also noted a lack of independent association between WMH and BP in patients with stroke.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p><p>The modest VRF effect is supported by RCTs. Antihypertensive treatment had no effect in the large PRoFESS (Prevention Regimen for Effectively Avoiding Second Strokes) MRI substudy (n = 771) after an average of 28 months<sup><xref rid="R12" ref-type="bibr">12</xref></sup>: insufficient BP lowering was blamed for not preventing WMH progression, but the average systolic/diastolic BP <italic>reduction</italic> in PRoFESS (3.0/1.3 mm Hg) was identical to the systolic/diastolic BP <italic>increment</italic> (3.0/2.0 mm Hg) blamed for WMH progression over only 14 months of follow-up in a 584-patient observational cohort.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Intensive vs usual antihypertensive treatment did not significantly reduce recurrent lacunar stroke.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> In RCTs of other VRF modifications that reduce adverse outcomes from LAD, statins had no effect in preventing WMH progression,<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and dual vs mono antiplatelet therapy caused excess hemorrhage and death without reducing recurrent stroke in patients with lacunar stroke.<sup><xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R20" ref-type="bibr">20</xref></sup> However, data on lipids and WMH are lacking and should be addressed in further studies.</p><p>Our study strengths include the large sample (total n = 1,118), a development (n = 861) and replication (n = 257) cohort, and robust statistics. The narrow age range of the LBC1936 subjects minimized the powerful confounding effect of age on WMH, LAD, and VRFs. The results were the same in the MSS patients whose ages spanned 6 decades and had more vascular disease. The LBC1936 subjects are all white Caucasian, minimizing any influence of ethnic differences on VRFs. We have no reason to think that our subjects are unrepresentative of other Caucasian cohorts (Scotland has one of the highest vascular disease rates in the world). A third of the LBC1936 and approximately 40% of MSS patients had moderate to severe WMH. We found the same results for WMH assessed by visual rating and volume. We carefully excluded infarcts from the WMH volume: inadvertent inclusion of infarcts in &#x0201c;WMH volume&#x0201d; may have inflated associations among VRFs, LAD, and WMH previously.<sup><xref rid="R28" ref-type="bibr">28</xref></sup></p><p>The study had limitations. We lacked continuous BP monitoring but used the average of 3 systolic and diastolic BP readings obtained over 4 hours at sitting positions by trained technicians. Most other studies of WMH and BP have not used continuous BP measures. Perhaps our subjects were too old: BP decreases between middle and old age<sup><xref rid="R38" ref-type="bibr">38</xref></sup>; WMH may be more closely associated with long-standing elevated BP from middle age.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> However, BP measured 3 years earlier at approximately age 69 was very similar; our &#x0201c;history of hypertension&#x0201d; captured prior hypertension and was the strongest risk factor. Age 72 is not particularly &#x0201c;old.&#x0201d; The stroke cohort including much younger subjects produced the same result. Future studies could test other BP parameters. Adding other imaging markers of SVD might increase the sensitivity for detecting causal relationships. Some variables were missing but without evidence of bias and we used all available data. The high prevalence of peripheral vascular disease in the LBC1936 may represent overreporting but is counterbalanced by the objective measure of peripheral vascular disease with the ABPI and by the MSS where history and examination were very detailed and the same associations were found.</p><p>Our results suggest that WMH have a large &#x0201c;nonvascular&#x0201d; component. The remaining unexplained 98% of WMH variance will hinder advances in prevention of dementia, stroke,<sup><xref rid="R1" ref-type="bibr">1</xref></sup> and physical dependency<sup><xref rid="R2" ref-type="bibr">2</xref></sup> in aging. Treating hypertension and diabetes, lowering cholesterol, and stopping smoking are important. Lifestyles that minimize vascular risk should be encouraged. Other modifiable risk factors (e.g., vitamins),<sup><xref rid="R39" ref-type="bibr">39</xref></sup> dietary factors (e.g., salt), inflammation, and other nonvascular contributing mechanisms should be sought.</p></sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Data Supplement</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_82_15_1331__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_WNL.0000000000000312_Supplemental_data.doc"/>
</supplementary-material>
</sec>
</body><back><fn-group><fn fn-type="supplementary-material"><p>Supplemental data at <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link></p></fn></fn-group><ack><title>ACKNOWLEDGMENT</title><p>The authors thank the radiographers at the Brain Research Imaging Centre; Elizabeth Eadie and Avril Thomas, ultrasonographers at the Department of Neuroradiology, Edinburgh (<ext-link ext-link-type="uri" xlink:href="http://www.bric.ed.ac.uk">www.bric.ed.ac.uk</ext-link>); the nurses of the Wellcome Trust Clinical Research Facility, Edinburgh (<ext-link ext-link-type="uri" xlink:href="http://www.wtcrf.ed.ac.uk">www.wtcrf.ed.ac.uk</ext-link>); P. Davies, J. Corley, A. Pattie, and R. Henderson for coordination, data collection, and entry for LBC1936; and the staff at Lothian Health Board and at the SCRE Centre, University of Glasgow.</p></ack><sec sec-type="contributions"><title>AUTHOR CONTRIBUTIONS</title><p content-type="contributions">J.M. Wardlaw, M. Allerhand, I. Deary, F. Doubal: study concept and design. F. Doubal, A. Gow, I. Deary, J. Starr, M. Bastin, M. Dennis, J.M. Wardlaw: acquisition of data. M. Allerhand, M. Valdez Hernandez, Z. Morris, F. Doubal, M. Dennis, I. Deary, J. Starr, J.M. Wardlaw: analysis and interpretation. I. Deary, M. Dennis, F. Doubal, M. Allerhand, M. Valdez Hernandez, A. Gow, J.M. Wardlaw: critical revision of the manuscript for important intellectual content. J.M. Wardlaw, I. Deary: study supervision.</p></sec><sec sec-type="funding"><title>STUDY FUNDING</title><p content-type="funding">The initial recruitment and testing of the LBC1936 was supported by Research Into Ageing: the subsequent imaging and related data collection used here was supported by Age UK (The Disconnected Mind project; the Sidney de Haan Award for Vascular Dementia) and the <funding-source>Medical Research Council</funding-source> (<award-id>G1001245</award-id> and <award-id>82800</award-id>). The MSS was funded by the Chief Scientist Office of the Scottish Executive (CZB/4/281) and the <funding-source>Wellcome Trust</funding-source> (<award-id>075611</award-id>). The Brain Research Imaging Centre is supported by the SINAPSE Collaboration (<ext-link ext-link-type="uri" xlink:href="http://www.sinapse.ac.uk/">www.sinapse.ac.uk</ext-link>) funded by the Scottish Funding Council and Chief Scientist Office and NHS Lothian Research and Development Office. The work was partly undertaken within the University of Edinburgh Centre for Cognitive Aging and Cognitive Epidemiology (<award-id>G0700704/84698</award-id>, <ext-link ext-link-type="uri" xlink:href="http://www.ccace.ed.ac.uk/">http://www.ccace.ed.ac.uk/</ext-link>), part of the cross council Lifelong Health and Wellbeing Initiative. Funding from the BBSRC, EPSRC, ESRC, and MRC is gratefully acknowledged. The study funders had no role in study design, data collection, analysis, interpretation, or writing of the report.</p></sec><sec sec-type="disclosure"><title>DISCLOSURE</title><p content-type="disclosure">The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type="uri" xlink:href="http://neurology.org/">Neurology.org</ext-link> for full disclosures.</p></sec><glossary><title>GLOSSARY</title><def-list><def-item><term id="G1">ABPI</term><def><p>ankle-brachial pressure index</p></def></def-item><def-item><term id="G2">BP</term><def><p>blood pressure</p></def></def-item><def-item><term id="G3">eGFR</term><def><p>estimated glomerular filtration rate</p></def></def-item><def-item><term id="G4">HbA1c</term><def><p>hemoglobin A1c</p></def></def-item><def-item><term id="G5">IMT</term><def><p>intima-media thickness</p></def></def-item><def-item><term id="G6">LAD</term><def><p>large-artery atheromatous disease</p></def></def-item><def-item><term id="G7">LBC1936</term><def><p>Lothian Birth Cohort 1936</p></def></def-item><def-item><term id="G8">MSS</term><def><p>Mild Stroke Study</p></def></def-item><def-item><term id="G9">RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term id="G10">SVD</term><def><p>small-vessel disease</p></def></def-item><def-item><term id="G11">VRF</term><def><p>vascular risk factor</p></def></def-item><def-item><term id="G12">WMH</term><def><p>white matter hyperintensity</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debette</surname><given-names>S</given-names></name><name><surname>Markus</surname><given-names>HS</given-names></name></person-group>
<article-title>The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis</article-title>. <source>BMJ</source>
<year>2010</year>;<volume>341</volume>:<fpage>c3666</fpage><pub-id pub-id-type="pmid">20660506</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baezner</surname><given-names>H</given-names></name><name><surname>Blahak</surname><given-names>C</given-names></name><name><surname>Poggesi</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>Association of gait and balance disorders with age-related white matter changes: the LADIS study</article-title>. <source>Neurology</source>
<year>2008</year>;<volume>70</volume>:<fpage>935</fpage>&#x02013;<lpage>942</lpage><pub-id pub-id-type="pmid">18347315</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Dichgans</surname><given-names>M</given-names></name></person-group>
<article-title>Mechanisms of sporadic cerebral small vessel disease: insights from neuroimaging</article-title>. <source>Lancet Neurol</source>
<year>2013</year>;<volume>12</volume>:<fpage>483</fpage>&#x02013;<lpage>497</lpage><pub-id pub-id-type="pmid">23602162</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>J</given-names></name><name><surname>Gardener</surname><given-names>H</given-names></name><name><surname>Rundek</surname><given-names>T</given-names></name><etal/></person-group>
<article-title>Baseline and longitudinal increases in diastolic blood pressure are associated with greater white matter hyperintensity volume: the Northern Manhattan Study</article-title>. <source>Stroke</source>
<year>2011</year>;<volume>42</volume>:<fpage>2639</fpage>&#x02013;<lpage>2641</lpage><pub-id pub-id-type="pmid">21836088</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Pantoni</surname><given-names>L</given-names></name><name><surname>Simoni</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Blood pressure components and changes in relation to white matter lesions: a 32-year prospective population study</article-title>. <source>Hypertension</source>
<year>2009</year>;<volume>54</volume>:<fpage>57</fpage>&#x02013;<lpage>62</lpage><pub-id pub-id-type="pmid">19487586</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>De Kersaint-Gilly</surname><given-names>A</given-names></name><name><surname>Besancon</surname><given-names>V</given-names></name><etal/></person-group>
<article-title>Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort</article-title>. <source>Neurology</source>
<year>2001</year>;<volume>56</volume>:<fpage>921</fpage>&#x02013;<lpage>926</lpage><pub-id pub-id-type="pmid">11294930</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leeuw</surname><given-names>FE</given-names></name><name><surname>de Groot</surname><given-names>JC</given-names></name><name><surname>Oudkerk</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Hypertension and cerebral white matter lesions in a prospective cohort study</article-title>. <source>Brain</source>
<year>2002</year>;<volume>125</volume>:<fpage>765</fpage>&#x02013;<lpage>772</lpage><pub-id pub-id-type="pmid">11912110</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottesman</surname><given-names>RF</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Catellier</surname><given-names>DJ</given-names></name><etal/></person-group>
<article-title>Blood pressure and white-matter disease progression in a biethnic cohort. Atherosclerosis Risk in Communities (ARIC) Study</article-title>. <source>Stroke</source>
<year>2010</year>;<volume>41</volume>:<fpage>3</fpage>&#x02013;<lpage>8</lpage><pub-id pub-id-type="pmid">19926835</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godin</surname><given-names>O</given-names></name><name><surname>Tzourio</surname><given-names>C</given-names></name><name><surname>Maillard</surname><given-names>P</given-names></name><name><surname>Mazoyer</surname><given-names>B</given-names></name><name><surname>Dufouil</surname><given-names>C</given-names></name></person-group>
<article-title>Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C)-Dijon Magnetic Resonance Imaging Study</article-title>. <source>Circulation</source>
<year>2011</year>;<volume>123</volume>:<fpage>266</fpage>&#x02013;<lpage>273</lpage><pub-id pub-id-type="pmid">21220733</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Leeuw</surname><given-names>FE</given-names></name><name><surname>de Groot</surname><given-names>JC</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><etal/></person-group>
<article-title>Carotid atherosclerosis and cerebral white matter lesions in a population based magnetic resonance imaging study</article-title>. <source>J Neurol</source>
<year>2000</year>;<volume>247</volume>:<fpage>291</fpage>&#x02013;<lpage>296</lpage><pub-id pub-id-type="pmid">10836622</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dufouil</surname><given-names>C</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Coskun</surname><given-names>O</given-names></name><etal/></person-group>
<article-title>Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy</article-title>. <source>Circulation</source>
<year>2005</year>;<volume>112</volume>:<fpage>1644</fpage>&#x02013;<lpage>1650</lpage><pub-id pub-id-type="pmid">16145004</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>R</given-names></name><name><surname>Weimar</surname><given-names>C</given-names></name><name><surname>Blatchford</surname><given-names>J</given-names></name><etal/></person-group>
<article-title>Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy</article-title>. <source>Stroke</source>
<year>2012</year>;<volume>43</volume>:<fpage>2336</fpage>&#x02013;<lpage>2342</lpage><pub-id pub-id-type="pmid">22738922</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benavente</surname><given-names>OR</given-names></name><name><surname>McClure</surname><given-names>LA</given-names></name><name><surname>Coffey</surname><given-names>CS</given-names></name><etal/></person-group>
<article-title>The secondary prevention of small subcortical strokes (SPS3) Trial: results of the blood pressure intervention</article-title>. <source>Lancet</source>
<year>2013</year>;<volume>382</volume>:<fpage>507</fpage>&#x02013;<lpage>515</lpage><pub-id pub-id-type="pmid">23726159</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><etal/></person-group>
<article-title>Different impacts of blood pressure variability on the progression of cerebral microbleeds and white matter lesions</article-title>. <source>Stroke</source>
<year>2012</year>;<volume>43</volume>:<fpage>2916</fpage>&#x02013;<lpage>2922</lpage><pub-id pub-id-type="pmid">22949472</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rost</surname><given-names>NS</given-names></name><name><surname>Rahman</surname><given-names>R</given-names></name><name><surname>Sonni</surname><given-names>S</given-names></name><etal/></person-group>
<article-title>Determinants of white matter hyperintensity volume in patients with acute ischemic stroke</article-title>. <source>J Stroke Cerebrovasc Dis</source>
<year>2010</year>;<volume>19</volume>:<fpage>230</fpage>&#x02013;<lpage>235</lpage><pub-id pub-id-type="pmid">20434052</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouw</surname><given-names>AA</given-names></name><name><surname>van der Flier</surname><given-names>WM</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><etal/></person-group>
<article-title>Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability Study</article-title>. <source>Stroke</source>
<year>2008</year>;<volume>39</volume>:<fpage>1414</fpage>&#x02013;<lpage>1420</lpage><pub-id pub-id-type="pmid">18323505</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Doubal</surname><given-names>FN</given-names></name><name><surname>Valdes-Hernandez</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Blood-brain barrier permeability and long term clinical and imaging outcomes in cerebral small vessel disease</article-title>. <source>Stroke</source>
<year>2013</year>;<volume>44</volume>:<fpage>525</fpage>&#x02013;<lpage>527</lpage><pub-id pub-id-type="pmid">23233386</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>ten Dam</surname><given-names>VH</given-names></name><name><surname>van den Heuvel</surname><given-names>DM</given-names></name><name><surname>van Buchem</surname><given-names>MA</given-names></name><etal/></person-group>
<article-title>Effect of pravastatin on cerebral infarcts and white matter lesions</article-title>. <source>Neurology</source>
<year>2005</year>;<volume>64</volume>:<fpage>1807</fpage>&#x02013;<lpage>1809</lpage><pub-id pub-id-type="pmid">15911821</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><collab>SPS3 Investigators</collab>. <article-title>Effects of clopidogrel added to aspirin in patients with recent lacunar stroke</article-title>. <source>N Engl J Med</source>
<year>2012</year>;<volume>367</volume>:<fpage>817</fpage>&#x02013;<lpage>825</lpage><pub-id pub-id-type="pmid">22931315</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Palacio</surname><given-names>S</given-names></name><name><surname>Hart</surname><given-names>RG</given-names></name><name><surname>Pearce</surname><given-names>LA</given-names></name><name><surname>Benavente</surname><given-names>OR</given-names></name></person-group>
<article-title>Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials</article-title>. <source>Stroke</source>
<year>2012</year>;<volume>43</volume>:<fpage>2157</fpage>&#x02013;<lpage>2162</lpage><pub-id pub-id-type="pmid">22826359</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Gow</surname><given-names>AJ</given-names></name><name><surname>Taylor</surname><given-names>MD</given-names></name><etal/></person-group>
<article-title>The Lothian Birth Cohort 1936: a study to examine influences on cognitive ageing from age 11 to age 70 and beyond</article-title>. <source>BMC Geriatr</source>
<year>2007</year>;<volume>7</volume>:<fpage>28</fpage><pub-id pub-id-type="pmid">18053258</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doubal</surname><given-names>FN</given-names></name><name><surname>MacGillivray</surname><given-names>TJ</given-names></name><name><surname>Hokke</surname><given-names>PE</given-names></name><name><surname>Dhillon</surname><given-names>B</given-names></name><name><surname>Dennis</surname><given-names>MS</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>
<article-title>Differences in retinal vessels support a distinct vasculopathy causing lacunar stroke</article-title>. <source>Neurology</source>
<year>2009</year>;<volume>72</volume>:<fpage>1773</fpage>&#x02013;<lpage>1778</lpage><pub-id pub-id-type="pmid">19451533</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Bastin</surname><given-names>ME</given-names></name><name><surname>Valdes Hernandez</surname><given-names>MC</given-names></name><etal/></person-group>
<article-title>Brain aging, cognition in youth and old age and vascular disease in the Lothian Birth Cohort 1936: rationale, design and methodology of the imaging protocol</article-title>. <source>Int J Stroke</source>
<year>2011</year>;<volume>6</volume>:<fpage>547</fpage>&#x02013;<lpage>559</lpage><pub-id pub-id-type="pmid">22111801</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lorenz</surname><given-names>MW</given-names></name><name><surname>Markus</surname><given-names>HS</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Rosvall</surname><given-names>M</given-names></name><name><surname>Sitzer</surname><given-names>M</given-names></name></person-group>
<article-title>Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis</article-title>. <source>Circulation</source>
<year>2007</year>;<volume>115</volume>:<fpage>459</fpage>&#x02013;<lpage>467</lpage><pub-id pub-id-type="pmid">17242284</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Lewis</surname><given-names>S</given-names></name></person-group>
<article-title>Carotid stenosis measurement on colour Doppler ultrasound: agreement of ECST, NASCET and CCA methods applied to ultrasound with intra-arterial angiographic stenosis measurement</article-title>. <source>Eur J Radiol</source>
<year>2005</year>;<volume>56</volume>:<fpage>205</fpage>&#x02013;<lpage>211</lpage><pub-id pub-id-type="pmid">15964165</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Chawluk</surname><given-names>JB</given-names></name><name><surname>Alavi</surname><given-names>A</given-names></name><name><surname>Hurtig</surname><given-names>HI</given-names></name><name><surname>Zimmerman</surname><given-names>RA</given-names></name></person-group>
<article-title>MR signal abnormalities at 1.5T in Alzheimer's dementia and normal aging</article-title>. <source>AJR Am J Roentgenol</source>
<year>1987</year>;<volume>149</volume>:<fpage>351</fpage>&#x02013;<lpage>356</lpage><pub-id pub-id-type="pmid">3496763</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valdes Hernandez</surname><given-names>MC</given-names></name><name><surname>Ferguson</surname><given-names>KJ</given-names></name><name><surname>Chappell</surname><given-names>FM</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>
<article-title>New multispectral MRI data fusion technique for white matter lesion segmentation: method and comparison with thresholding in FLAIR images</article-title>. <source>Eur Radiol</source>
<year>2010</year>;<volume>20</volume>:<fpage>1684</fpage>&#x02013;<lpage>1691</lpage><pub-id pub-id-type="pmid">20157814</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Valdes Hernandez</surname><given-names>MC</given-names></name><name><surname>Doubal</surname><given-names>F</given-names></name><name><surname>Chappell</surname><given-names>FM</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group>
<article-title>How much do focal infarcts distort white matter lesions and global cerebral atrophy measures?</article-title>
<source>Cerebrovasc Dis</source>
<year>2012</year>;<volume>34</volume>:<fpage>336</fpage>&#x02013;<lpage>342</lpage><pub-id pub-id-type="pmid">23154746</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>J</given-names></name><name><surname>Weisberg</surname><given-names>S</given-names></name></person-group>
<source>An R Companion to Applied Regression</source>, <edition>2nd ed</edition>
<publisher-loc>Thousand Oaks</publisher-loc>: <publisher-name>Sage Publications</publisher-name>; <year>2011</year></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Child</surname><given-names>D</given-names></name></person-group>
<source>The Essentials of Factor Analysis</source>, <edition>3rd ed</edition>
<publisher-loc>London</publisher-loc>: <publisher-name>Continuum International Publishing Group</publisher-name>; <year>2006</year></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Muth&#x000e9;n</surname><given-names>LK</given-names></name><name><surname>Muth&#x000e9;n</surname><given-names>BO</given-names></name></person-group>
<source>Mplus User's Guide</source>, <edition>6th ed</edition>
<publisher-loc>Los Angeles</publisher-loc>: <publisher-name>Muth&#x000e9;n &#x00026; Muth&#x000e9;n</publisher-name>; <year>2010</year></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preacher</surname><given-names>KJ</given-names></name><name><surname>Hayes</surname><given-names>AF</given-names></name></person-group>
<article-title>SPSS and SAS procedures for estimating indirect effects in simple mediation models</article-title>. <source>Behav Res Methods Instrum Comput</source>
<year>2004</year>;<volume>36</volume>:<fpage>717</fpage>&#x02013;<lpage>731</lpage><pub-id pub-id-type="pmid">15641418</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Preacher</surname><given-names>KJ</given-names></name><name><surname>Hayes</surname><given-names>AF</given-names></name></person-group>
<article-title>Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models</article-title>. <source>Behav Res Methods</source>
<year>2008</year>;<volume>40</volume>:<fpage>879</fpage>&#x02013;<lpage>891</lpage><pub-id pub-id-type="pmid">18697684</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Donnell</surname><given-names>MJ</given-names></name><name><surname>Xavier</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal/></person-group>
<article-title>Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE Study): a case-control study</article-title>. <source>Lancet</source>
<year>2010</year>;<volume>376</volume>:<fpage>112</fpage>&#x02013;<lpage>123</lpage><pub-id pub-id-type="pmid">20561675</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>EJ</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><etal/></person-group>
<article-title>The association between blood pressure, hypertension, and cerebral white matter lesions: Cardiovascular Determinants of Dementia Study</article-title>. <source>Hypertension</source>
<year>2004</year>;<volume>44</volume>:<fpage>625</fpage>&#x02013;<lpage>630</lpage><pub-id pub-id-type="pmid">15466662</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Dijk</surname><given-names>EJ</given-names></name><name><surname>Prins</surname><given-names>ND</given-names></name><name><surname>Vrooman</surname><given-names>HA</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name></person-group>
<article-title>Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences: Rotterdam Scan Study</article-title>. <source>Stroke</source>
<year>2008</year>;<volume>39</volume>:<fpage>2712</fpage>&#x02013;<lpage>2719</lpage><pub-id pub-id-type="pmid">18635849</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glymour</surname><given-names>MM</given-names></name><name><surname>Weuve</surname><given-names>J</given-names></name><name><surname>Berkman</surname><given-names>LF</given-names></name><name><surname>Kawachi</surname><given-names>I</given-names></name><name><surname>Robins</surname><given-names>JM</given-names></name></person-group>
<article-title>When is baseline adjustment useful in analyses of change? An example with education and cognitive change</article-title>. <source>Am J Epidemiol</source>
<year>2005</year>;<volume>162</volume>:<fpage>267</fpage>&#x02013;<lpage>278</lpage><pub-id pub-id-type="pmid">15987729</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wills</surname><given-names>AK</given-names></name><name><surname>Lawlor</surname><given-names>DA</given-names></name><name><surname>Matthews</surname><given-names>FE</given-names></name><etal/></person-group>
<article-title>Life course trajectories of systolic blood pressure using longitudinal data from eight UK cohorts</article-title>. <source>PLoS Med</source>
<year>2011</year>;<volume>8</volume>:<fpage>e1000440</fpage><pub-id pub-id-type="pmid">21695075</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavalieri</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group>
<article-title>B vitamins and magnetic resonance imaging&#x02013;detected ischemic brain lesions in patients with recent transient ischemic attack or stroke: the VITAmins TO Prevent Stroke (VITATOPS) MRI-substudy</article-title>. <source>Stroke</source>
<year>2012</year>;<volume>43</volume>:<fpage>3266</fpage>&#x02013;<lpage>3270</lpage><pub-id pub-id-type="pmid">23093615</pub-id></mixed-citation></ref></ref-list></back></article>
